Business
InflaRx Presents New Preclinical Findings for INF904 at the 19th European Meeting on Complement in Human Diseases
JENA, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting
About this update from Inflarx N.v.
[{"type":"text","content":"JENA, Germany, Sept. 03, 2024 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, today announced the presentation of preclinical data for the company’s novel oral C5aR inhibitor, INF904, at the 2024 European Meeting on Complement in Human Diseases (EMCHD) being held in Lübeck, Germany, September 2 – 6, 2024. Members of InflaRx leadership also participated in a satellite symposium highlighting the role of the C5a/C5aR1 axis in driving inflammation and served as the biopharma industry representative on a panel focused on the relevance of targeting C3 and C5. InflaRx also hosted a lunch seminar focused on C5a/C5aR inhibition in human disease with best-in-class compounds. Camilla Chong, MD, Chief Medical Officer of InflaRx, commented: “We welcome the opportunity to demonstrate our commitment to advancing the science of complement inhibition and progress toward our goal of developing first-in-class and best-in-class anti-inflammatory therapies via inhibition of C5a and C5aR. The preclinical findings presented at EMCHD 2024 from multiple in vivo and ex vivo models provide strong evidence of INF904’s significant anti-inflammatory properties and strong pharmacokinetic properties, further supporting our belief that INF904 may have differentiating advantages as a member of the C5aR inhibitor drug class.” Preclinical pharmacological characterization of INF904, an oral small molecule antagonist to complement 5a receptor1 (C5aR1)Rui Liu, Zhongli Xu, Ophelia Chen, Bruce P. Burnett, Maria Habel, Renfeng Guo Overall, this study demonstrated that INF904 is a highly selective and potent inhibitor of C5aR1 with promising pharmacokinetic (PK) properties, while also exhibiting strong efficacy potential in vivo. Both INF904 and avacopan were evaluated through a series of cell-based, ex vivo, and in vivo assays. In a hamster neutropenia model, INF904 inhibited C5a-induced neutropenia by 96.5% compared to 51.1% for the same dose of avacopan. INF904 also demonstrated a more favorable PK profile with 2- to 5-fold higher exposure than avacopan across all tested animal species. The data also indicated that INF904 is a much weaker inhibitor of CYP3A4/5, with an IC50 value of 62 µM, compared to 1.7 µM for avacopan. CYP3A4/5 enzymes play an important role in t...